CC BY-NC-ND 4.0 · Avicenna J Med 2022; 12(02): 081-086
DOI: 10.1055/s-0042-1750391
Original Article

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit

1   Department of Emergency Medicine, Adiyaman University Medical Faculty, Adıyaman, Turkey
,
1   Department of Emergency Medicine, Adiyaman University Medical Faculty, Adıyaman, Turkey
,
1   Department of Emergency Medicine, Adiyaman University Medical Faculty, Adıyaman, Turkey
,
1   Department of Emergency Medicine, Adiyaman University Medical Faculty, Adıyaman, Turkey
,
1   Department of Emergency Medicine, Adiyaman University Medical Faculty, Adıyaman, Turkey
,
Cihad Sonmez
1   Department of Emergency Medicine, Adiyaman University Medical Faculty, Adıyaman, Turkey
,
1   Department of Emergency Medicine, Adiyaman University Medical Faculty, Adıyaman, Turkey
› Author Affiliations
Funding None.

Abstract

Background Currently, the most effective method in the fight against coronavirus disease 2019 (COVID-19) is vaccination against the disease. However, there are hesitations among society concerning the safety and side effects of COVID-19 vaccines. We aimed to determine the observed side effects that require an emergency room visit after taking the BNT162b2 and CoronaVac vaccines.

Methods This prospective observational study was conducted with patients who presented to the emergency department due to vaccine-related complications after COVID-19 vaccination. The patients' symptoms at the time of presentation, time from vaccination to the onset of symptoms, and dose of the vaccine administered were determined. In addition, the demographic characteristics of the patients, whether they had a history of COVID-19 infection, and their vital signs at the time of presentation were recorded. The variables were compared according to the type of vaccine administered.

Results The study included 182 patients who presented to the emergency department over a 6-month period. It was determined that 166 of these patients (91.2%) had received the BNT162b2 vaccine and 16 (8.8%) had received the CoronaVac vaccine. The majority of the patients did not have a history of COVID-19 infection (70.3%), and most presented to the hospital with complications after the second dose (61%). The onset of vaccine-related symptoms was mostly within 1 to 12 hours (39%). The majority of patients (97.8%) were discharged from the emergency department. The most common symptoms after vaccination were fatigue (n = 70), followed by muscle/joint pain (n = 52), headache (n = 33), and fever (n = 32). The rate of dizziness was found to be statistically significantly higher in the CoronaVac vaccine group than in the BNT162b2 vaccine group (p = 0.008). There was no statistically significant difference between the two vaccine groups in relation to the remaining symptoms (p > 0.005).

Conclusion There were no serious complications related to the BNT162b2 or CoronaVac vaccine. The most common symptom after both vaccines was fatigue; therefore, the BNT162b2 and CoronaVac vaccines can be safely administered.

Authors' Contributions

E. Y. and K. T. conceived and designed the project. U. G., E. A., and I. A. acquired, analyzed, and interpreted the data. C. S. and O. O. wrote the original draft manuscript. E. Y., K. T., and U. G. wrote, revised, and edited the manuscript.




Publication History

Article published online:
03 July 2022

© 2022. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Ita K. Coronavirus disease (COVID-19): current status and prospects for drug and vaccine development. Arch Med Res 2021; 52 (01) 15-24
  • 2 Wibawa T. COVID-19 vaccine research and development: ethical issues. Trop Med Int Health 2021; 26 (01) 14-19
  • 3 Haidere MF, Ratan ZA, Nowroz S. et al. COVID-19 vaccine: critical questions with complicated answers. Biomol Ther (Seoul) 2021; 29 (01) 1-10
  • 4 Petousis-Harris H. Correction to: assessing the safety of COVID-19 vaccines: a primer. Drug Saf 2021; 44 (04) 507
  • 5 Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go?. Expert Rev Vaccines 2021; 20 (01) 23-44
  • 6 Republic of Turkey Ministry of Health. COVID-19 vaccine information platform. Available at: https://covid19asi.saglik.gov.tr
  • 7 Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against coronaviruses: the state of the art. Vaccines (Basel) 2020; 8 (02) 309
  • 8 Yavuz E. COVID-19 vaccines. Turk J Family Practi 2020; 24 (04) 227-234
  • 9 Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022; 48 (01) 8-14
  • 10 Thaler J, Ay C, Gleixner KV. et al. Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). J Thromb Haemost 2021; 19 (07) 1819-1822
  • 11 Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021; 144 (06) 471-484
  • 12 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007; 85 (11) 867-872
  • 13 Lucia VC, Kelekar A, Afonso NM. COVID-19 vaccine hesitancy among medical students. J Public Health (Oxf) 2021; 43 (03) 445-449
  • 14 Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis 2020; 14 (12) e0008961
  • 15 Polack FP, Thomas SJ, Kitchin N. et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383 (27) 2603-2615
  • 16 CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep 2021; 70 (02) 46-51
  • 17 Bogdanov G, Bogdanov I, Kazandjieva J, Tsankov N. Cutaneous adverse effects of the available COVID-19 vaccines. Clin Dermatol 2021; 39 (03) 523-531
  • 18 Baden LR, El Sahly HM, Essink B. et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384 (05) 403-416
  • 19 Koizumi T, Awaya T, Yoshioka K. et al. Myocarditis after COVID-19 mRNA vaccines. QJM 2021; 114 (10) 741-743
  • 20 Cabanillas B, Akdis CA, Novak N. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?. Allergy 2021; 76 (06) 1617-1618
  • 21 Li J, Hui A, Zhang X. et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med 2021; 27 (06) 1062-1070
  • 22 Sadoff J, Le Gars M, Shukarev G. et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021; 384 (19) 1824-1835